Blood pressure and cardiovascular outcomes in high-risk Hispanics
This article has no abstract so we have provided the first paragraph of the full text.
Hispanics have an increased likelihood of possessing certain risk factors for coronary artery disease (CAD), including hypertension, but clinical trial data guiding treatment of this group are lacking. Using information from the prospective, randomized INVEST trial, which compared atenolol and sustained-release-verapamil strategies in a large cohort of patients with CAD and hypertension, Cooper-DeHoff et al. compared blood pressure control and risk of clinical adverse outcomes in Hispanic and non-Hispanic patients.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
